US 12,404,509 B2
Oligonucleotide-based proteolysis targeting chimera
Marcin Kortylewski, Monrovia, CA (US); Piotr Marek Swiderski, San Dimas, CA (US); and Steven Rosen, Duarte, CA (US)
Assigned to City of Hope, Duarte, CA (US)
Appl. No. 17/251,549
Filed by City of Hope, Duarte, CA (US)
PCT Filed Jun. 17, 2019, PCT No. PCT/US2019/037447
§ 371(c)(1), (2) Date Jun. 25, 2021,
PCT Pub. No. WO2019/241766, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/685,810, filed on Jun. 15, 2018.
Prior Publication US 2021/0269803 A1, Sep. 2, 2021
Int. Cl. C12N 15/117 (2010.01); A61K 47/54 (2017.01); C12N 15/113 (2010.01)
CPC C12N 15/117 (2013.01) [A61K 47/545 (2017.08); A61K 47/549 (2017.08); C12N 15/113 (2013.01); C12N 2310/13 (2013.01); C12N 2310/14 (2013.01); C12N 2310/17 (2013.01); C12N 2310/315 (2013.01); C12N 2310/351 (2013.01)] 20 Claims
 
1. A compound comprising:
(i) a nucleic acid having at least 90% sequence identity to a nucleic acid selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:8; and
(ii) one or more ubiquitin ligase binding compounds selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
wherein the nucleic acid is covalently bonded to the one or more ubiquitin ligase binding compounds.